Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting ...Middle East

- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D - - 9 of 12 patients who underwent stem cell transplant after achieving a response with revumenib remained in remission, with four...

Hence then, the article about syndax announces positive updated data from phase 1 portion of augment 101 trial of revumenib in patients with acute leukemias during oral presentations at 64th ash annual meeting was published today ( Sunday 11/12/2022 - 01:36 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting )

Also on site :

• The NFL Names Its First-Ever 'Chief Kindness Officer' Ahead of Super Bowl LX
• 1990 Tearjerker Voted ‘Best Country Song’ of All Time
• Firefighters fight police in France (VIDEOS)